Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience a significant symptom burden and a reduced life expectancy. Patients with MF receive ruxolitinib as the current standard of care, but the depth and durability of responses and the percentage of patients achieving clinical outcome measures are limited; thus, a significant unmet medical need exists. Pelabresib is an investigational small-molecule bromodomain and extraterminal domain inhibitor currently in clinical development for MF. The aim of this article is to describe the design of the ongoing, global, phase III, double-blind, placebocontrolled MANIFEST-2 study evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with JAKi treatment-naive MF.Plain language summary: Myelofibrosis (MF) is a rare type of blood cancer that interferes with the process of blood cell production by the bone marrow. In patients with MF, the bone marrow becomes overactive, leading to scarring and subsequently a lack of healthy blood cells being produced. The main symptoms of MF include anemia, fatigue, weakness and pain or discomfort in the abdomen. MF is associated with a shortened life expectancy. The current go-to treatment for MF is ruxolitinib. However, ruxolitinib has shown limited efficacy in improving clinical symptoms long term; so, new safe and effective treatments are needed. Pelabresib is a novel drug currently in clinical development for treating MF. The aim of this article is to describe the design of the ongoing, global phase III MANIFEST-2 study. MANIFEST-2 is evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with MF.[GRAPHICS].

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis / Harrison, Claire N; Gupta, Vikas K; Gerds, Aaron T; Rampal, Raajit; Verstovsek, Srdan; Talpaz, Moshe; Kiladjian, Jean-Jacques; Mesa, Ruben; Kuykendall, Andrew T; Vannucchi, Alessandro M; Palandri, Francesca; Grosicki, Sebastian; Devos, Timothy; Jourdan, Eric; Wondergem, Marielle J; Al-Ali, Haifa Kathrin; Buxhofer-Ausch, Veronika; Alvarez-Larrán, Alberto; Patriarca, Andrea; Kremyanskaya, Marina; Mead, Adam J; Akhani, Sanjay; Sheikine, Yuri; Colak, Gozde; Mascarenhas, John. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - ELETTRONICO. - 18:(2022), pp. 2987-2997. [10.2217/fon-2022-0484]

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Vannucchi, Alessandro M
Writing – Original Draft Preparation
;
2022

Abstract

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience a significant symptom burden and a reduced life expectancy. Patients with MF receive ruxolitinib as the current standard of care, but the depth and durability of responses and the percentage of patients achieving clinical outcome measures are limited; thus, a significant unmet medical need exists. Pelabresib is an investigational small-molecule bromodomain and extraterminal domain inhibitor currently in clinical development for MF. The aim of this article is to describe the design of the ongoing, global, phase III, double-blind, placebocontrolled MANIFEST-2 study evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with JAKi treatment-naive MF.Plain language summary: Myelofibrosis (MF) is a rare type of blood cancer that interferes with the process of blood cell production by the bone marrow. In patients with MF, the bone marrow becomes overactive, leading to scarring and subsequently a lack of healthy blood cells being produced. The main symptoms of MF include anemia, fatigue, weakness and pain or discomfort in the abdomen. MF is associated with a shortened life expectancy. The current go-to treatment for MF is ruxolitinib. However, ruxolitinib has shown limited efficacy in improving clinical symptoms long term; so, new safe and effective treatments are needed. Pelabresib is a novel drug currently in clinical development for treating MF. The aim of this article is to describe the design of the ongoing, global phase III MANIFEST-2 study. MANIFEST-2 is evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with MF.[GRAPHICS].
18
2987
2997
Harrison, Claire N; Gupta, Vikas K; Gerds, Aaron T; Rampal, Raajit; Verstovsek, Srdan; Talpaz, Moshe; Kiladjian, Jean-Jacques; Mesa, Ruben; Kuykendall, Andrew T; Vannucchi, Alessandro M; Palandri, Francesca; Grosicki, Sebastian; Devos, Timothy; Jourdan, Eric; Wondergem, Marielle J; Al-Ali, Haifa Kathrin; Buxhofer-Ausch, Veronika; Alvarez-Larrán, Alberto; Patriarca, Andrea; Kremyanskaya, Marina; Mead, Adam J; Akhani, Sanjay; Sheikine, Yuri; Colak, Gozde; Mascarenhas, John
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1286387
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact